Cryo-electron microscopy studies (Li et al., 2024, Cell Discovery) revealed the peptide adopts a single continuous helix achieving balanced activation through conserved interactions and receptor-specific transmembrane domain contacts
Macro vascular complications are still the primary cause of death in patients with T2DM.Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a new class of Injectable Anti-diabetes Agents (IADA) that provides blood glucose control with weight reduction ability, systolic blood pressure reduction and a noticeable improvement of lipid profile
GLP-1 receptor agonists work by mimicking the incretin hormone glucagon-like peptide-1, which enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety
While still in trials, there are different types of delivery systems been studied for GLP-1 drug transdermal patches
Los agonistas del receptor de pptido similar al glucagn-1 (ArGLP-1) son una herramienta clave en el manejo multidisciplinario de la obesidad y la diabetes mellitus tipo 2 (DM2) [1]
Cameron-Vendrig, A
